Shaji Kumar, MD, is a Professor of Medicine and Consultant at the Mayo Clinic, in Rochester, MN. He completed his medical studies at the All-India Institute of Medical Sciences in New Delhi, India, after which he completed an internal medicine residency and hematology/oncology fellowship at the Mayo Clinic School of Graduate Medical Education in Rochester, MN.
Prof. Kumar is Treasurer of the International Myeloma Society, Chair of the Myeloma, Amyloid and Dysproteinemia DOG, and has been the Chair of the plasma cell disorders scientific committee for the American Society of Hematology since 2019. He also contributes to the editorial advisory board of The Lancet Hematology and the American Journal of Hematology.
Speaking on novel therapies and combination regimens for multiple myeloma
Prof. Kumar conducts research into the translation of novel therapeutic targets in multiple myeloma, as well as novel drug development and evaluation of combinations of therapies that act synergistically to improve outcomes in multiple myeloma. To achieve one of his research goals of improving understanding of this cancer, he also studies myeloma biology, especially the effect of the bone marrow microenvironment and the onset and biomarkers for progression of monoclonal gammopathies.